Schering-Plough reports loss on merger charges
95723
Drug maker Schering-Plough Corp  on Tuesday reported a fourth-quarter loss as special charges from its acquisition of Organon Biosciences late last year offset sharply higher sales.
77782
Schering-Plough Corp  on Monday reported third-quarter profit and sales that fell short of Wall Street's target, sending shares down more than 10 percent amid concerns about its flagship cholesterol drugs.
456781
The Schering-Plough Corporation has agreed to pay $435 million and plead guilty to conspiracy to settle charges of marketing drugs for unapproved uses and overcharging Medicaid.
372947
Stocks of branded and generic drug makers closed down a bit Tuesday as clinical study results mixed with merger updates. One of the big winners on the day was Nektar Therapeutics, on news that Exubera, the
292602
Drugmaker Mylan Laboratories Inc.  posted a quarterly loss on Thursday on charges related to an acquisition, but reported adjusted profit that beat its previous forecast helped by sales of generic drugs for pain and bladder control.
457209
Akzo Nobel  said on Monday it was selling its drugs unit Organon BioSciences to Schering-Plough  for 11 billion euros ($14.4 billion), in a last-minute reversal of plans to float it on the stock market.
594500
Schering-Plough Corp. SGP.N on  Thursday reported a quarterly profit after a year-ago loss, as  positive foreign exchange trends helped offset poor sales of  its allergy and hepatitis drugs.
274554
Germany's Deutsche Post AG said  losses at its U.S. express and logistics business will be 200  million euros ($246.1 million) greater than expected this year,  sending its shares down over 4 percent.
672686
Germany&#39;s Bayer AG has entered into a strategic pharmaceuticals alliance with Schering-Plough, Bayer said Monday. It said Schering-Plough would market and distribute some Bayer
378404
Charges hurt the quarterly results of  Johnson & Johnson, Merck & Co. and Schering-Plough Corp., but  the drugmakers' shares rose as J&J's earnings beat Wall Street  forecasts and Merck sales edged higher despite the withdrawal  of its best-selling Vioxx arthritis drug.
647411
Bristol-Myers Squibb Co  reported a quarterly loss on Thursday due to special charges, including a $275 million write-down from the credit crisis spreading through corporate America.
336343
Merck posted a $1.63 billion fourth-quarter loss on Wednesday as charges for its Vioxx litigation settlement dragged down results and share prices.
633510
Eli Lilly and Co.  on Wednesday reported a fourth-quarter net loss on charges for restructuring and taxes related to the return of overseas profits as sales of prescription drugs rose only slightly.
83518
Merck & Co and Schering-Plough Corp said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.
770376
OSI Pharmaceuticals Inc. on Monday posted a wider loss for the year ended Sept. 30, hurt by greater research and development costs and one-time charges during the period.
70317
MedImmune Inc. reported a third-quarter loss yesterday, despite $61 million in sales of its lead product, Synagis, a 25 percent increase over the same period a year ago.
750251
BOSTON (CBS.MW) -- Pharmaceutical conglomerates Schering-Plough and Bayer have entered into a broad joint-marketing deal Monday for several of the companies&#39; leading drugs.